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Abstract
Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, limiting muscle regeneration and
resulting in fibrotic and fatty tissue replacement of muscle, which exacerbates the wasting process in dystrophic muscles.
Limiting immune response is thus one of the therapeutic options to improve healing, as well as to improve the efficacy of
gene- or cell-mediated strategies to restore dystrophin expression. Protein kinase C h (PKCh) is a member of the PKCs family
highly expressed in both immune cells and skeletal muscle; given its crucial role in adaptive, but also innate, immunity, it is
being proposed as a valuable pharmacological target for immune disorders. In our study we asked whether targeting PKCh
could represent a valuable approach to efficiently prevent inflammatory response and disease progression in a mouse
model of muscular dystrophy. We generated the bi-genetic mouse model mdx/h
2/2, where PKCh expression is lacking in
mdx mice, the mouse model of Duchenne muscular dystrophy. We found that muscle wasting in mdx/h
2/2 mice was greatly
prevented, while muscle regeneration, maintenance and performance was significantly improved, as compared to mdx
mice. This phenotype was associated to reduction in inflammatory infiltrate, pro-inflammatory gene expression and pro-
fibrotic markers activity, as compared to mdx mice. Moreover, BM transplantation experiments demonstrated that the
phenotype observed was primarily dependent on lack of PKCh expression in hematopoietic cells. These results
demonstrate a hitherto unrecognized role of immune-cell intrinsic PKCh activity in the development of DMD. Although the
immune cell population(s) involved remain unidentified, our findings reveal that PKCh can be proposed as a new
pharmacological target to counteract the disease, as well as to improve the efficacy of gene- or cell- therapy approaches.
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Introduction
Duchenne muscular dystrophy (DMD) is one of the most
common X-linked lethal diseases, and results from the mutation
within the gene encoding dystrophin, a large cytoskeletal protein,
whose ablation leads to membrane instability [1]. Therapies based
on the restoration of dystrophin expression or the administration
of dystrophin
+ve stem cells are promising, but still in the preclinical
phase [2–4]. In this context, one of the barrier to successful gene
therapy has been recently identified in cellular immunity [5].
Thus, the monitoring of cellular immune responses should be a
priority for any experimental therapy designed to increase the
number of dystrophin-positive myofibers in patients with Duch-
enne’s muscular dystrophy. In addition, although mechanical
injury and membrane defects are important factors promoting
dystrophic pathology, increasing evidences highlight aberrant
intracellular signalling cascades that regulate inflammatory and
immune processes, as key contributors to the degenerative process
[1,6]. Up-regulated inflammatory gene expression and activated
immune cell infiltrates are evident during early disease stages in
dystrophic muscle, and the identification of specific targets for
anti-inflammatory therapies is one of the ongoing therapeutic
options. Indeed, glucocorticoids, which have anti-inflammatory
properties, are being used to treat DMD with some success;
however, the side effects of these drugs often outweigh their benefit
[7,8]. Numerous other anti-inflammatory therapies have been
proposed to improve healing [9–13]. In this context, it has been
recently shown that rapamycin treatment reduced dystrophic
phenotype in mdx mice and that this effect was associated to a
significant reduction in infiltration of Teff cells in skeletal muscle
tissue, while Treg cells were preserved [14]. Indeed, a role of
lymphocytes activity in the progression of muscular dystrophy is
long known, as antibody- or genetic-mediated lymphocyte
depletion improved the disease in mdx, however, not all studies
had produced definitive results, and the implication of lympho-
cytes and their subtypes in the disease is still to be clearly defined.
Among the possible targets, genetic and pharmacological evidenc-
es suggest that protein kinase C (PKC) isotypes have essential
functions in promoting both early T-cell activation and sustained
T-cell adhesion and are proposed as drug targets in adaptive
immunity [15]. Among the isotypes, PKCh is unique in its ability
to translocate to the immunological synapses upon T-cell receptor
(TCR) activation, regulating NFkB, AP-1, and NFAT transcrip-
tional activity [16]. PKCh can also directly associate to chromatin,
regulating T-cell-specific inducible gene expression program and
microRNAs [17]. It is worth noting that PKCh has been recently
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mediated suppression [18]. Indeed, PKCh is being proposed as a
particularly attractive target for developing ways to selectively
manipulate Teff cell functions that are relevant to pathogenesis of
different diseases, including asthma, rheumatoid arthritis, multiple
sclerosis and colitis [15,19–21], without imparting a severe
immunosuppression. Interestingly, PKCh is the PKC isoform
predominantly expressed also in skeletal muscle, where it mediates
various cellular responses [22–27]. Although most of these studies
demonstrated that PKCh is actually required for complete
histogenesis, differentiation and homeostasis of skeletal muscle,
we asked which would be its prevalent role in a context of chronic
inflammation, where immune cells activity is a key determinant as
in muscular dystrophy. We here demonstrate that immune-cell
intrinsic PKCh activity plays a crucial role in the progression of
muscular dystrophy, and targeting PKCh can be proposed as a
valuable therapeutic strategy for the disease.
Results
Lack of PKCh in mdx mice reduces muscle degeneration
and inflammation
To verify whether inhibition of PKCh may improve healing in
muscular dystrophy, we crossed the PKCh knock out model
(PKCh
2/2) with mdx, the mouse model of DMD. We first
observed, by Western blot analysis, that PKCh was highly
expressed in both WT and mdx hindlimb muscle, but a
significantly higher portion of it was phosphorylated, as a feature
of its activation [16], in the mdx, as compared to WT (Fig. 1A). As
expected, no dystrophin expression was detectable in the mdx and
mdx/h
2/2 muscle, and no PKCh immunoreactivity in the mdx/
h
2/2 muscle (Fig. 1A). Both mutants were healthy at birth. We
thus evaluated myofiber degeneration in diaphragm (as being
diaphragm one of the most affected muscle group in mdx) and in
tibialis anterior (TA) of 2 mo old mice, as Evan’s blue dye (EBD)
uptake. As shown in Figure 1B and C (a–b), myofiber
degeneration was significantly reduced in both muscles derived
from mdx/h
2/2 in respect to mdx. As expected, those degenerating
areas were sites of a robust inflammatory response, as shown by
anti-mouse IgG immunofluorescence (Fig. 1C, c–d). Indeed,
while degenerating fibers in mdx muscle were surrounded by many
mononucleated cells, degenerating fibers in mdx/h
2/2were almost
avoided of surrounding mononucleated cells, and mouse IgGs
were strictly localized on the fiber itself (Fig. 1D). Accordingly,
Western Blot analysis revealed that the IgG content in the protein
extract from mdx/h
2/2 muscle was greatly lower than that from
mdx (Fig. 1E). Hematoxilin/Eosin (H/E) staining of TA muscle
sections, showed that lack of PKCh resulted in significant
reduction in cell infiltrate as compared to mdx (Fig. 2A), leading
to an overall maintenance of muscle structure; however, the
myofibers variability and the percentage of centro-nucleated
myofibers over the total number of fibers (as features of dystrophic
muscle) were similar between the two genotypes (Fig. 2B–C). As
being macrophage infiltration the most prominent immune feature
observed in mdx [6], TA cryosections were analysed for esterase
activity. As shown in Figure 2D, the areas of macrophages
Figure 1. Lack of PKCh in mdx mice reduces muscle degener-
ation. (A) Representative western blot analysis of total protein fraction
of TA muscles derived from 2 mo old WT, PKCh
2/2, mdx and mdx/h
2/2
mice, as indicated. The blot was incubated with the indicated primary
antibodies. GAPDH expression level is shown in the bottom for equal
loading. PKCh activation in muscle derived from mdx (black bar) mice,
expressed as fold induction in respect to WT (white bar, assumed as 1),
is shown as the ratio of pPKCh/PKCh (right panel), as determined by
densitometric analysis from three independent experiments (*p,0.05).
(B) EBD uptake in diaphragm derived from 2 mo old mdx or mdx/h
2/2
mice, as indicated, shown under light (a, c) and epifluorescence (b, d)
microscopy. (C) EBD uptake in TA muscle derived from 2 mo old mdx
(a)o rmdx/h
2/2 (b) mice, as indicated; immunofluorescence analysis of
IgG accumulation in mdx (c)o rmdx/h
2/2 (d) mice; bar=200 mm. (D)
Mononuclear cells accumulation, revealed as Hoechst staining, around
single degenerating fiber, detected as EBD uptake (a–b) and IgG
immunofluorescence (c–d), in TA muscles from mdx (a and c)o rmdx/
h
2/2 (b and d). (E) Representative western Blot analysis of IgG
accumulation in TA muscles from mdx or mdx/h
2/2 (two mice/
genotype), as indicated. Densitometric analysis is shown in the bottom
(mdx, black bar; mdx/h
2/2, grey bar, *p,0.05).
doi:10.1371/journal.pone.0031515.g001
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2/2 muscle were strongly reduced;
accordingly, FACS analysis of CD45/Mac-3 co-expressing cells,
revealed that the level of macrophages was reduced by <50% in
2 mo old mdx/h
2/2 muscle, as compared to mdx (Fig. 2E).
Macrophages are known to store and produce matrix metallopro-
teinase 9 (MMP-9) in response to different stimuli, such as
oxidative stress from necrotic tissue, and represent the major
source of MMP-9 [28]. Indeed, the high level of MMP9 activity
observed in mdx, was strongly prevented in mdx/h
2/2 muscle, as
shown by zymography (Fig. 2F). Moreover, as shown in Figure 3,
lack of PKCh strongly prevented the hyper-expression/activation
of pro-inflammatory signalling pathways; in fact, both the level of
expression and of phosphorylation of the p65 subunit of NFkB and
of JNK in mdx/h
2/2 TA muscle were much lower than in mdx,
very similar to the level observed in WT. The p65 subunit of NFkB
is the NFkB subunit mostly hyperactive in mdx muscle [11] and
JNK is the upstream regulator of AP1 signalling pathway, which is
also hyperactive in mdx [1].
Lack of PKCh in mdx mice improves muscle regeneration
To verify whether the observed reduction in muscle wasting and
cell infiltrate came along with improvement in muscle repair,
muscle regeneration was analysed in the mutant mice by both
morphological and biochemical analyses. Immunofluorescence
analysis of embryonic myosin (eMyHC) expression, a marker of
regenerating myofibers, revealed that lack of PKCh resulted in an
increase on eMyHC expressing myofibers along with a reduction
in EBD positive myofibers (Fig. 4A). Indeed, quantitative analysis
revealed that the extension of ‘‘regenerating area’’, including
eMyHC expressing fibers, was significantly higher in mdx/h
2/2,a s
compared to mdx muscle, parallel to a significant decrease in
‘‘degenerating area’’, including EBD stained fibers (Fig. 4A).
Accordingly, the level of myogenin expression, a marker of
differentiating myoblasts, was strongly increased in mdx/h
2/2,a s
compared to mdx muscle (Fig. 4B). Intriguingly, we previously
showed that PKCh is actually required for myofiber growth both
in vivo and in vitro, as being an upstream regulator of the expression
of pro-fusion genes [27]. To unravel the apparent contradiction
with our current results, in vitro differentiation of primary
myoblasts derived from mdx and from mdx/h
2/2 hindlimb muscle
was compared. As shown in Figure 4C, by 48 hours in DM, mdx
myoblasts had formed elongated myotubes containing a large
number of nuclei; by contrast, mdx/h
2/2 myoblasts formed
thinner myotubes with reduced number of myonuclei, according
to our previous observation in PKCh
2/2 myoblasts. Taken
together, these results suggest that lack of PKCh in mdx makes a
more favourable environment for muscle precursor cells to
differentiate, rather than enhancing their activation/differentia-
tion ability. Indeed, though the regenerating area in vivo was more
extensive in mdx mice lacking PKCh, as compared to mdx, cross-
Figure 2. Lack of PKCh in mdx mice reduces cell infiltrate in
muscle. (A) Hematoxylin/Eosin staining of TA crysosections derived
from 2 mo old mdx (a, c) and mdx/h
2/2 (b, d). The insets in a and b
indicate the areas shown in c and d, respectively, at higher
magnification; bar=100 mm. (B) Myofiber variability coefficient in TA
muscles derived from 2 mo old WT, mdx and mdx/h
2/2, determined as
described in the material and methods sections. (n=3/genotype). (C)
Percentage of centrally nucleated myofibers in TA muscles derived from
2 mo old mdx and mdx/h
2/2, expressed as percentage over the total
number of myofibers (n=3/genotype). (D) Esterase histochemical
staining of TA cryosections derived from 2 mo old mdx and mdx/h
2/2
mice, as indicated. Arrows indicate cell infiltrates, arrows indicate
neuromuscular junctions. Bar=200 mm( E) FACS analysis of CD45
+ve/
Mac3
+ve mononucleated cells isolated from TA muscle derived from
2m o o l d mdx and mdx/h
2/2 mice, as indicated, expressed as
percentage of the total number of cells examined. The percentage of
reduction in mdx/h
2/2muscle, in respect to mdx, is also shown (n=3/
genotype). (F) Gel zymography of MMP9 activity in TA muscle derived
from 2 mo old mdx and mdx/h
2/2 mice, as indicated; media collected
from differentiating muscle cell cultures was used as positive control
(+).
doi:10.1371/journal.pone.0031515.g002
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medially reduced by <15%, as a result of PKCh.ablation.
Lack of PKCh in mdx mice preserves exercise
performance
To verify whether the improvement in muscle maintenance and
regeneration resulted in better performance, a treadmill endur-
ance test was performed and the number of times the mice stopped
during the 30 min running, each day of the test, was recorded. As
expected, mdx mice stopped increasing times during individual
running (not shown) and, medially, many more times than WT
mice, in each day examined (Fig. 5). Importantly, mdx/h
2/2 mice
behaved very similar to WT, both during the running than in all
days examined (Fig. 5).
Rescue of PKCh expression in hematopoietic cells in
mdx/h
2/2 mice, by bone marrow transplantation, partly
restores mdx mice phenotype
To verify whether the obtained phenotype was actually due to
alterations in inflammatory cells activity, 1 mo old mdx bone
marrow (BM) was transplanted into irradiated, age and sex
matching mdx/h
2/2 mice. In these mice, hereafter called
mdx/h
2/2BMmdx, PKCh was thus expressed only in the BM-
derived cells. As control, another group of age and sex matching
mdx/h
2/2 mice was transplanted with BM derived from mdx/h
2/2,
hereafter called mdx/h
2/2BMmdx/h2/2. The mice were sacrificed 6
weeks after transplantation and BM repopulation was ensured by
genomic PCR analysis, as the appearance of the PKCh WT PCR
product (Fig. 6A). Western blot analysis revealed that PKCh
expression was largely rescued in thymus derived from
mdx/h
2/2BMmdx transplanted mice, while the expression of other
PKC isoforms was unaltered (Fig. 6B), and immunofluorescence
analysis revealed that PKCh expressing cells were detectable in
the spleen (Fig. 6C), demonstrating that engrafted hematopoietic
cells repopulated also mature compartments. H/E staining of TA
muscle crysections derived from mdx/h
2/2BMmdx revealed a
significant increase of infiltrating cells (Fig. 7A, e), as compared
to those derived from mdx/h
2/2BMmdxh2/2 (Fig. 7A, a), which
were mostly macrophages, as shown by esterase histochemistry
(Fig. 7A, f). Moreover, EBD uptake revealed an increase in
degenerating myofibers in the mdx/h
2/2BMmdx (Fig. 7A, g), as
compared to mdx/h
2/2BMmdxh2/2 (Fig. 7A, c), parallel to a
reduction in eMyHC expressing fibers (Fig. 7A, h) to levels
comparable to mdx, as shown by quantitative analyses (Fig. 7B).
Accordingly, iNOS expression, as a marker of macrophage
infiltration, increased, as well as both NFkB and JNK expression
and activity (Fig. 7C). However, the observed worsen phenotype
was not translated in worsened exercise performance, as both
mdx/h
2/2BMmdx and mdx/h
2/2BMmdxh2/2 behaved similar to WT
mice in a treadmill endurance test (Fig. 7D).
Discussion
We show in this article that lack of PKCh in mdx prevents
muscle wasting while improving muscle structure, regeneration
and performance. This phenotype is associated to, and, probably,
dependent on, reduced inflammation, which could make a more
favourable environment for muscle precursor cells to differentiate.
The mdx mouse strain is the most widely used animal model for
DMD; although it presents a milder phenotype compared to
DMD, the immune cell populations in their muscles resemble
those seen in DMD patients [6]. As first, we found that PKCh is
highly phosphorylated/active in mdx muscle as compared to WT
muscle, and its lack significantly reduced muscle necrosis evaluated
as EBD positive fibers in both DIA and TA. Interestingly, not only
the percentage of degenerating myofibers was reduced, but also
were sites of IgG accumulation. As PKCh deficient mice have
been shown to mount a significantly reduced lung inflammation
response to antigen challenge and exhibit reduced inflammation in
rodent models of arthritis as well as in autoimmune disease, the
possibility that the improved phenotype was dependent on its
activity on promoting inflammation is thus reasonable. Indeed, we
show that lack of PKCh in mdx resulted in significantly reduced
macrophages infiltration, as revealed by both IHC and FACS
analysis. Macrophages are the primary immune cells evident in
skeletal muscle of mdx mice together to T-cells and neutrophils, as
being macrophage infiltration the most prominent immune feature
observed [6]. The reduction in macrophages is probably
responsible for the reduction in the MMP-9 accumulation
observed. Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases, have been shown to play an important
role in ECM degradation, inflammation, fibrosis, and activation of
latent cytokines and cell adhesion molecules in different patho-
physiological conditions, including muscular dystrophies [28]. In
particular, the expression of MMP-9 is increased in dystrophic
muscle and its inhibition, either genetic or pharmacological,
considerably reduces inflammatory response, fibrosis, and enhanc-
es the myofiber regeneration in mdx mice [28]. Moreover, we show
that lack of PKCh prevented the hyper-activation of the pro-
inflammatory pathways NFkB and AP1, known to be up-regulated
in mdx. It is worth noting that chronic activation of NF-kB
signalling is required for DMD pathology by acting both on
Figure 3. Lack of PKCh in mdx mice prevents up-regulation of
pro-inflammatory pathways. Left panel: representative Western Blot
analysis of total protein fraction of TA muscles derived from 2 mo old
WT, mdx and mdx/h
2/2 mice, as indicated. The blot was incubated with
the anti- p-NF-kB p65, NF-kB p65, - p-JNK, - JNK antibodies, as indicated.
GAPDH level of expression was used for normalization. The p-p65NFkB/
p65NFkB (top) and of p-JNK/JNK (both p46 and p54) (bottom) ratio, as
determined by densitometric analysis from three independent exper-
iments, is shown in the right, expressed as fold induction in respect to
WT (assumed as 1, dotted line). *p,0.01 in respect to WT.
doi:10.1371/journal.pone.0031515.g003
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mation and to inhibit myogenic differentiation of muscle
precursors [29]. Genetic and pharmacological studies demonstrat-
ed that inhibition of NFkB signalling reduced inflammation and
necrosis enhancing regeneration and implicated the NFkB
signalling pathway as a potential therapeutic target for this disease
[11,30]. Also AP-1 activity is increased early in mdx muscle, and is
supposed to be implicated in the activation of many inflammatory
cytokines and chemokines [31]. Thus, the observed reduction in
these pathways in mdx muscle lacking PKCh may contribute to
favour muscle healing. It is well known that the inflammatory
response negatively contributes to the limited ability of dystrophic
muscle to regenerate. Indeed, muscle regeneration is the initial
response to muscle damage, but, in Duchenne muscular
dystrophy, muscle progenitor cells activation/differentiation is
limited [32,33]. This fact depends mainly to the exhaustion of
muscle progenitor cells pool, due to the continuous cycles of
degeneration/regeneration [32,33], but also chronic inflammation
contributes to make an unfavourable environment for their
activation/differentiation. As we show here, lack of PKCh in
mdx actually favoured muscle regeneration, as demonstrated by the
increase in eMyHC expressing fibers and by myogenin up-
regulation. In this context, sustained myogenin expression in mdx/
h
2/2 muscle may theoretically contribute to myofiber metabolic
changes, which, in turn, may be involved in muscle wasting
prevention and physiology improvement. In fact, several observa-
tions suggested that myogenin may participate in at least a part of
a fast-to-slow fiber-type transition [34,35]. Although further
Figure 4. Lack of PKCh in mdx mice improves muscle regeneration. (A) eMyHC immunofluorescence (green) in TA cryosections derived from
mdx (a and d) and mdx/h
2/2 (b and e) mice, as indicated. Merge with EBD uptake (red) is shown in d (mdx) and e (.mdx/h
2/2). Bar=200 mm.
Extension of regenerating, eMyHC
+ve, area (c) and of necrotic, EBD
+ve, area (f)i nmdx/h
2/2, expressed as the percentage in respect to the respective
areas in mdx (assumed as 1); *p,0.01, n=3/genotype. Bar=200 mm. (B) Representative Western Blot analysis of total protein fraction of TA muscles
derived from 2 mo old WT, mdx and mdx/h
2/2 mice, as indicated, incubated with the a-myogenin antibody; Red Ponceau staining of the membrane
is shown for equal loading. Up-regulation of myogenin expression in mdx/h
2/2, in respect to mdx (assumed as 1), muscles, as determined by
densitometric analysis of three independent experiments is shown in the bottom (n=3/genotype) (C) Representative Wright staining of mdx- and
mdx/h
2/2- muscle derived cells, as indicated, cultured in DM for 48 hrs. The mean number of nuclei contained within each myotube is shown, as well
as the percentage of reduction in mdx/h
2/2 in respect to mdx, as determined from three independent experiments.
doi:10.1371/journal.pone.0031515.g004
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enzymes were observed in mdx/h
2/2 muscle, as compared to mdx
(Madaro et al. unpublished observation). The observed myogenin
up-regulation should thus primarily reflect the increase in
differentiating satellite cells, as a feature of regenerating muscle,
rather than a sustained myogenin expression. These results may
appear in contrast with our previous observation showing that
PKCh
2/2 regenerating muscle displayed the characteristics of
delayed regeneration, as compared to time-matching regenerating
WT muscle. However, those effects were not due to an
impairment in muscle precursors activation/differentiation, rather
to an impairment of the late phases of growth/regeneration
process, delaying further addition of myonuclei to newly formed
myofibers, due to reduction in the expression of the so-called pro-
fusion genes. Indeed, we show in this paper that primary cells
derived from mdx/h
2/2 muscle formed thinner myotubes with
reduced number of myonuclei in vitro, as we observed in PKCh
2/2
muscle cells, when compared to those derived from mdx muscle. It
is thus conceivable that in mdx chronic inflammation contributes
significantly in preventing activation of muscle precursor cells,
which however are able to efficiently differentiate, as they do ex
vivo. By contrast, lack of PKCh, though delaying the fusion process
itself, makes a more favourable environment for muscle precursors
cells to differentiate by reducing inflammation, thus allowing
muscle repair. Indeed, mdx/h
2/2 regenerating myofiber CSA was
reduced, as compared to mdx. As a result, muscle tissue structure is
preserved, though the myofiber CSA variability and the
percentage of centrally-nucleated myofibers were similar to those
in mdx. Importantly, lack of PKCh preserved exercise performance
in mdx, suggesting that the improved phenotype correlates to
improved functionality of the muscle. Taken together, these results
demonstrate that lack of PKCh in mdx mice dramatically reduces
cell infiltration and inflammation, improving muscle regeneration
and performance, suggesting a hitherto unrecognized crucial role
of PKCh in promoting immune response in muscular dystrophy.
Consistent with this hypothesis, PKCh expressing BM derived cells
partly counteracted improvement in inflammation, muscle wasting
and regeneration in mdx/h
2/2 mice, as shown by BM transplan-
tation experiments. Intriguingly, exercise performance was not
impaired, instead. This fact may depend on the time required for
muscle to decline its functionality: it is conceivable that 6 weeks
upon BM transplantation were sufficient to partly restore immune
response, which however was still less than in age-matching mdx,
but not to worsen muscle performance. Although the specific cell
population(s) involved is not clear yet, an attractive hypothesis
would be that lack of PKCh prevents Teff cells activity, while
maintaining Treg cells activity, which in turn may modulate
macrophages phenotype and activity. However, as PKCh lacks in
all cells in the mdx/h
2/2 model, the possible contribution of other
tissue components, in particular skeletal muscle, in the observed
phenotype cannot be ruled out. In any case, the results obtained
demonstrate that PKCh expression/activity in immune cells is
required for the robust inflammatory response in mdx, which, in
turn, exacerbates the muscle pathology. Further studies are needed
to verify long term efficacy, as well as the effect of targeting PKCh
in older animals, when pathological features are already
established. Moreover, as being muscular dystrophy a multi-
factorial disease, in which inflammation plays a crucial role, the
possibility to combine PKCh targeting as anti-inflammatory
therapy, to other gene- or cell- based therapeutic approaches to
significantly improve and optimize the therapeutic efficacy, should
be explored [5]. The availability, and the ongoing development, of
Figure 5. Lack of PKCh in mdx mice preserves exercise performance. Treadmill exercise test performed on 2 mo old WT, mdx and mdx/h
2/2
mice (n=6 each genotype) for a 30 min running, twice a week, for 3 weeks. The average number of stops recorded from mice of each genotype in
each day, during the 30 min running, is shown in the left (WT, black line; mdx, dotted line; mdx/h
2/2, grey line). The extreme time points (1st and 6th
days) performance were not included. Same results are expressed as percentage in respect to WT mice (assumed as 100%; mdx/h
2/2, grey bars; mdx,
black bars) in the right, for each day performance.
doi:10.1371/journal.pone.0031515.g005
Figure 6. Rescue of PKCh expression in hematopoietic cells in
mdx/h
2/2 mice, by bone marrow transplantation. (A) PCR analysis
of BM cell suspension genomic DNA derived from mdx/h
2/2BMmdx/h2/2
and from mdx/h
2/2BMmdx, as indicated. The reappearance of the 400 kb
PCR product from the PKCh gene in mdx/h
2/2BMmdx is shown. (B)
Western Blot analysis of PKCh, PKCd and PKCa expression in total
protein extract from thymi derived from mdx/h
2/2BM mdx/h2/2 and from
mdx/h
2/2BMmdx.( C) Immunofluorescence analysis of PKCh-expressing
cells (green) in the spleens derived from mdx/h
2/2BMmdx/h2/2 and from
mdx/h
2/2BMmdx. Hoechst was used to counterstain the nuclei (blue).
doi:10.1371/journal.pone.0031515.g006
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trials for immune disorders, thus opens new perspectives for
pharmacological approach to muscular dystrophy [15,19].
Methods
Mice
PKCh
2/2 mice were gently provided by Prof Dan Littman
[36]. Mdx mice were purchased from Charles River. The mice
were cross-bread to generate Mdx/h
2/2 double mutant mice.
C57BL10 WT mice (Charles River) were used as control. The
animals were housed at the Histology Unit accredited animal
facility, in individual cages in an environmentally controlled room
(23uC, 12-h light-dark cycle) and provided food and water ad
libitum. All the procedures were approved by the Italian Ministry
for Health and conducted according to the US National Institutes
of Health guidelines.
Antibodies
The anti-PKC-h and the anti-phospho
Thr538 PKC-h, the anti-
p65NFkB, the anti-phospho p65NFkB, the anti- JNK and the anti-
phospho JNK rabbit polyclonal antibodies were purchased from
Cell Signalling Inc., Danvers, MA, USA; the anti-iNOS mouse
monoclonal antibody was from BD Bioscience, CA, USA, while
the anti-dystrophin was from Leica Microsystems, Germany; the
anti-myogenin F5D and the anti-embryonic myosin heavy chain
F1.652 mouse monoclonal antibodies were from Developmental
Studies Hybridoma Bank, Iowa City, Iowa, USA.
Primary muscle cell cultures
Primary cultures were prepared from total limb muscles of mdx
or mdx/h
2/2. mice, as previously described [27]. Muscle derived
cells were grown on collagen-coated dishes, in growth medium,
GM (Dulbecco’s modified Eagle’s medium, D-MEM containing
20% HS, 3% EE, all from Gibco Invitrogen, Carlsbad, CA, USA)
in a humidified 5% CO2 atmosphere at 37uC. Differentiation was
induced by replacing the medium with medium containing lower
serum and EE concentration, DM (D-MEM containing 5% HS,
0,75% EE). The cells were fixed after 48 hrs in DM and stained
with Wright’s solution. The mean number of nuclei contained
within each myotube was determined as previously described [27].
Approximately 100 myotubes were counted per dish.
Histological and immunohistochemical analyses
Muscle cryosections were fixed in 4% paraformaldehyde
(Sigma-Aldrich, MO, USA) on ice. Myofiber necrosis was
evaluated on muscle cryosections prepared from mice intraperi-
toneally injected with a 1% Evan’s Blue Dye solution (EBD,
Sigma-Aldrich, MO, USA), at 1% volume relative to body mass,
between 16 and 24 h prior to tissue sampling. The samples were
analyzed under an epifluorescence Zeiss Axioskop 2 Plus
microscope. For histological analysis, muscle cryosections were
stained with Hematoxylin/Eosin solution (Sigma-Aldrich, MO,
USA). The muscle fiber mean cross sectional area (CSA) was
determined by measuring CSA of fibres in the entire section, using
Scion Image 4.0.3.2 software (NIH, Bethesda, MA, USA).
Myofiber variability was determined by multiplying the standard
deviation of all measurements by 1,000 and dividing it by the
mean fiber diameter [37]. Esterase localization and activity was
evaluated on cryosections by esterase staining (a-naphthyl
butyrate/hexazotized pararosaniline).
Immunofluorescence analysis on crysections was performed as
previously described [27]. Nuclei were counterstained with
Hoechst 33342 (Fluka, WI, USA) and the samples were analyzed
under an epifluorescence Zeiss Axioskop 2 Plus microscope.
Gelatin zymography
Muscle extracts were prepared in non-reducing lysis buffer
[50 mM Tris-Cl (pH 8.0), 200 mM NaCl, 50 mM NaF, 0.3%
IGPAL CA-630 and protease inhibitors], as previously described
[28]. Equal amount of proteins was separated on 8% SDS–PAGE
containing 1 mg/ml gelatin B (Fisher Scientific) under non-
reducing conditions. Gels were washed in 2.5% Triton X-100 for
1 h at room temperature followed by incubation in reaction buffer
[50 mM Tris–HCl (pH 8.0), 50 mM NaCl, 5 mM CaCl2 and
0.02% sodium azide] for 48 h at 37uC. To visualize gelatinolytic
bands, gels were stained with Coomassie Brilliant Blue dye,
followed by extensive washing in destaining buffer (40%
methanol/10% acetic acid).
Western blot analysis
Tissue samples were homogenized in ice-cold buffer containing
20 mM Tris (pH 7.5), 2 mM EDTA, 2 mM EGTA, 250 mM
sucrose, 5 mM DTT, 200 mg/ml leupeptin, 10 mg/ml Trasylol,
1 mM PMSF, and 0.1% Triton X-100, as previously described
[27]. An equal amount of protein from each sample was loaded
onto 10% SDS-polyacrylamide gels and transferred to a
nitrocellulose membrane (Schleicher and Schuell, Dassel, Ger-
many). The membranes were incubated with the appropriate
primary antibodies, and processed as described [27]. Densitomet-
ric analysis was performed using the Aida 2.1 ImageH software.
Flow Cytometry Analysis. Mononuclear cell population was
isolated from dissected muscles by enzymatic digestion. 10
6 cells
were incubated on ice with 1 mg of the anti- Mac-3 FITC-labelled
and of the anti-CD45 PE-labelled antibodies (BD Biosciences, CA,
USA) and analysed with a FacsStar Plus cytofluorimeter. Non-
specific fluorescent emission was determined with the specific
labelled isotypes.
Treadmill exercise performance
Mice were first acclimated to the treadmill (LE 8710, PanLab
S.L.U., Barcelona, Spain) before running by placing them on an
Figure 7. Rescue of PKCh expression in hematopoietic cells in mdx/h
2/2 mice restores mdx mice phenotype. (A) H/E (a and e) and
esterase (b and f, arrows indicate cell infiltrates, asterisks indicate neuromuscular junctions) as well as EBD uptake (c and g) and eMyHC
immunofluorescence (d and h, Hoechst was used to counterstain the nuclei) of TA cryosections derived from mdx/h
2/2BMmdx/h2/2 (a–d) and from
mdx/h
2/2BMmdx (e–h) mice. Bar=200 mm. (B) Extension of regenerating, eMyHC
+ve, area and of necrotic, EBD
+ve, area in mdx/h
2/2BMmdx/h2/2 and in
mdx/h
2/2BMmdx expressed as the percentage in respect to the respective areas in mdx (assumed as 1), *p,0.05, n=3/genotype; (C) Western Blot
analysis of iNOS expression, and of NFkB and JNK expression and activation (phosphorylation) in protein extracts from TA muscle derived from mdx/
h
2/2BMmdx/h2/2 and from mdx/h
2/2BMmdx; red Ponceau staining of the membrane is shown (loading) for equal loading. Representative blots are
shown. The level of expression or of the activation of the above molecules was determined by densitometric analysis and expressed as fold induction
in mdx/h
2/2BMmdx in respect to mdx/h
2/2BMmdx/h2/2, assumed as 1, evaluated from 3 separate experiments (bottom). *p,0.05 (D) Treadmill exercise
test performed on mdx/h
2/2BMmdx/h2/2 (squares, dotted grey line) and mdx/h
2/2BMmdx (circles, grey.line) mice for a 30 min running, twice a week, for
3 weeks, as above, starting 6 weeks after transplantation (n=3/genotype). Performance of mdx (triangles, black line) and mdx/h
2/2 (rhombi, dotted
black line) mice is also reported for comparison.
doi:10.1371/journal.pone.0031515.g007
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15 cm/sec. The test ran for 30 min, and the number of times at
which mice failed to keep running, was recorded. Each test was
performed twice a week for three weeks, and the results were
averaged for each mouse.
Bone Marrow transplantation
1 mo old mdx/h
2/2 mice were X-irradiated (8 Gy per mouse)
by a Siemens linear accelerator operating at 10 MV, at a rate of
3 Gy/min. At 2 h postirradiation, the mice were intravenously
injected with bone marrow cell suspension derived from age-
matching mdx or mdx/h
2/2 mice. Mice were sacrificed 6 weeks
after transplantation, and bone marrow, thymus and spleen were
evaluated for exogenous cells accumulation. Different muscles
were dissected for morphological and molecular analyses.
PCR genotyping
Genomic DNA PCR, for PKCh
2/2 mutation, was conducted
as previously described [36]. A 700 bp PCR fragment is expected
for the mutated PKCh gene, while a 400 bp PCR fragment for the
WT one.
Statistical analysis
Quantitative data are presented as means 6 SEM or 6 SD (as
specified) of at least three independent experiments. Statistical
analysis to determine significance was performed using paired
Student’s t tests. Differences were considered to be statistically
significant at the p,0.05 level.
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